Key facts
| Price (PPV) | 95.90 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | pramipexole |
| Class | Anti-parkinson drugs |
| ATC code | N04BC05 |
| Manufacturer | BOTTU S.A. |
| Presentation | Boite de 30 |
| Nature | Médicament |
| Hospital price | 59.90 MAD |
| Data collected on | 9/8/2026 |
Indications
Pramipexol est indiqué chez les adultes pour le traitement des symptômes et signes de la maladie de Parkinson idiopathique, en monothérapie (sans lévodopa) ou en association à la lévodopa, quand au cours de l’évolution de la maladie, au stade avancé, l’effet de la lévodopa s’épuise ou devient inconstant et que des fluctuations de l’effet thérapeutique apparaissent (fluctuations de type fin de dose ou effets "on-off").
Psychoactive substance / dependence
Oui
Find an open pharmacy
On-call pharmacies near you
About Sifrol 0.26 mg
Sifrol 0.26 mg belongs to the anti-parkinson drugs therapeutic class. In Morocco, this drug is marketed by BOTTU S.A. and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Sifrol 0.26 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Sifrol 0.26 mg
Answers to common questions from Moroccan patients about this drug.